ADPT (Adaptive Biotechnologies) Future 3-5Y EPS without NRI Growth Rate : 20.68 (As of Jan. 19, 2025)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate is 20.68.

Competitive Comparison of Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate falls into.

Adaptive Biotechnologies (NAS:ADPT) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Adaptive Biotechnologies Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Executives

Kyle Piskel	officer: Principal Accounting Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Stacy L Taylor	officer: SVP and General Counsel	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Tycho Peterson	officer: Chief Financial Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Sharon Benzeno	officer: Chief Commercial Ofc Imm Med	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo	officer: Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Chad M Robins	director, officer: CEO and Chairman	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Julie Rubinstein	officer: President	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Susan Bobulsky	officer: SVP, Diagnostics, clonoSEQ	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood	officer: Chief Commercial Officer, MRD	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
R Mark Adams	officer: Chief Operating Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Katey Einterz Owen	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins	officer: Chief Scientific Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005